Abstract AI-generated illustration. Decorative artwork, not a depiction of data, molecules, or products.

A familiar peptide name does not always identify one chemical entity. It may point to a sequence, modified molecule, salt, conjugate, metal complex, fragment, or mixture. Identity has to be resolved before evidence, status, or a structure image can be transferred.

The atlas records that chain under Identity and structure assets and keeps product authentication separate in Product quality, authenticity, and testing.

Name-to-asset provenance chain
Identity provenance from a common name to an asset and source sidecarSix identity stages lead to a sourced asset, while mixture and ambiguous-identity branches end with no single depiction. GHK-Cu, TB-500, thymalin, and cerebrolysin remain caveated.commonnamealiasessequence +modificationschemicalformdatabaseidentifiersasset + sourcesidecarmixturethymalin / cerebrolysinambiguous identityGHK-Cu / TB-500NO SINGLE DEPICTIONdocument the boundary; do not invent precision
A database identifier and generated asset follow identity resolution; neither authenticates a physical sample.
Text alternative

Common name leads to aliases, sequence and modifications, chemical form, database identifiers, and an asset with a source sidecar. Mixtures and ambiguous identities stop at no single depiction. GHK-Cu, TB-500, thymalin, and cerebrolysin retain their documented caveats.

Sequence sources

Biological sequences are checked first against authoritative records such as UniProt, NCBI Protein, or a primary sequence publication. Synthetic analogues require the modified residue order plus terminal changes, crosslinks, lipidation, glycosylation, pegylation, stereochemistry, or other defining chemistry.

A one-letter sequence alone may omit exactly the feature that distinguishes a medicine from an peptide. The identity record therefore keeps the displayed sequence, modification notes, and source together.

Form distinctions

Identity issueWhy it mattersExisting exampleAtlas treatment
Salt or conjugateCounterions or attached groups can change the chemical entity and product recordSemaglutide has defining sequence modificationsRecord the exact modified form; do not transfer an unmodified depiction
Metal complexA peptide name and a database complex can have different stoichiometric scopeGHK-CuRetain the bis-complex caveat on the cited PubChem asset
MixtureOne name may cover many peptides without one sequence or molecular formulaThymalin and cerebrolysinRecord the mixture boundary; omit a false single structure
Stereochemistry or modificationResidue order can look identical while three-dimensional chemistry differsModified clinical analoguesRecord stereochemical and modification context with the sequence
Fragment ambiguityA market label may refer to full-length protein or a shorter fragmentTB-500Preserve both documented meanings and avoid one universal depiction

PubChem structures and their limits

PubChem is useful for stable identifiers, formulae, molecular weights, and standardized two-dimensional records. It is an evidence pointer, not proof that every material sold under a similar name has that identity.

A two-dimensional asset also omits conformational dynamics, formulation state, impurities, aggregation, counterion context, and sample provenance. For macromolecules or undefined mixtures, UniProt, ChEBI, a primary paper, or an explicit “no single depiction” record may be more accurate than a forced PubChem image.

Boundary cases with ambiguous identity

The atlas keeps unresolved boundaries visible:

  • GHK-Cu distinguishes free GHK from copper complexes and notes that the retained PubChem record represents a particular complex rather than every use of the name.

  • TB-500 records both the full-length thymosin beta-4 association and the shorter marketed fragment rather than treating them as interchangeable.

  • Thymalin and cerebrolysin are heterogeneous tissue-derived mixtures, so one sequence, formula, or structure would create false precision.

An unresolved identity is not filled by guesswork. The record states what is known, what remains ambiguous, and why a single asset is omitted.

Asset provenance

Every generated structure asset should carry a source sidecar recording the identifier, retrieval date, source URL, generation method, and caveat. That makes the image auditable and refreshable instead of decorative.

The provenance chain does not authenticate a physical sample. Authentication requires sample-specific analytical evidence and validated comparison standards; a database image cannot supply that evidence.

Refresh policy

Identity records and assets are refreshed when a source database changes, a better authoritative record appears, or the atlas resolves a previously ambiguous form. The last-verified date records when the source chain was checked, not a guarantee that no later correction exists.

Identity verification matters because every downstream statement depends on scope. A study of one sequence or pharmaceutical form does not automatically support a fragment, complex, mixture, or marketed material with a similar name.

Questions

Does one peptide name always mean one substance?

No; a familiar name may refer to different forms, fragments, complexes, conjugates, or mixtures.

Does a PubChem image authenticate a sample?

No; a database image documents a referenced chemical record, while sample authentication requires sample-specific analytical evidence.

Why has the generic GHK-Cu asset caveat been retained?

The cited PubChem record represents a particular copper complex and therefore cannot depict every use of the broader GHK-Cu name.

What happens when identity cannot be resolved?

The atlas records the ambiguity, states the boundary, and omits a falsely precise sequence, identifier, or structure.

Research updates

Join the atlas. Get the evidence updates.

Receive concise notes when peptide evidence, status, or source records change.